ASX - By Stock
|
NOX |
Re:
Ann: Veyonda Showing Potential to Prevent Cytokine Storm
|
|
vrs37
|
42 |
10K |
3 |
22/04/21 |
22/04/21 |
ASX - By Stock
|
42
|
10K
|
3
|
|
ASX - By Stock
|
OSL |
Re:
Article Supporting Oncosil Trial
|
|
vrs37
|
21 |
9.0K |
0 |
20/04/21 |
20/04/21 |
ASX - By Stock
|
21
|
9.0K
|
0
|
|
ASX - By Stock
|
OSL |
Re:
Article Supporting Oncosil Trial
|
|
vrs37
|
21 |
9.0K |
0 |
20/04/21 |
20/04/21 |
ASX - By Stock
|
21
|
9.0K
|
0
|
|
ASX - By Stock
|
OSL |
Re:
Article Supporting Oncosil Trial
|
|
vrs37
|
21 |
9.0K |
0 |
20/04/21 |
20/04/21 |
ASX - By Stock
|
21
|
9.0K
|
0
|
|
ASX - By Stock
|
OSL |
Re:
Article Supporting Oncosil Trial
|
|
vrs37
|
21 |
9.0K |
0 |
20/04/21 |
20/04/21 |
ASX - By Stock
|
21
|
9.0K
|
0
|
|
ASX - By Stock
|
OSL |
Re:
Article Supporting Oncosil Trial
|
|
vrs37
|
21 |
9.0K |
0 |
20/04/21 |
20/04/21 |
ASX - By Stock
|
21
|
9.0K
|
0
|
|
ASX - By Stock
|
OSL |
Re:
Article Supporting Oncosil Trial
|
|
vrs37
|
21 |
9.0K |
0 |
20/04/21 |
20/04/21 |
ASX - By Stock
|
21
|
9.0K
|
0
|
|
ASX - By Stock
|
OSL |
Re:
Theraspheres and FDA approval
|
|
vrs37
|
23 |
11K |
1 |
18/04/21 |
18/04/21 |
ASX - By Stock
|
23
|
11K
|
1
|
|
ASX - By Stock
|
NOX |
Re:
Company Maker?
|
|
vrs37
|
11 |
3.9K |
4 |
17/04/21 |
17/04/21 |
ASX - By Stock
|
11
|
3.9K
|
4
|
|
ASX - By Stock
|
NOX |
Re:
Company Maker?
|
|
vrs37
|
11 |
3.9K |
4 |
16/04/21 |
16/04/21 |
ASX - By Stock
|
11
|
3.9K
|
4
|
|
ASX - By Stock
|
OSL |
Re:
Theraspheres and FDA approval
|
|
vrs37
|
23 |
11K |
1 |
01/04/21 |
01/04/21 |
ASX - By Stock
|
23
|
11K
|
1
|
|
ASX - By Stock
|
OSL |
Re:
Theraspheres and FDA approval
|
|
vrs37
|
23 |
11K |
1 |
01/04/21 |
01/04/21 |
ASX - By Stock
|
23
|
11K
|
1
|
|
ASX - By Stock
|
OSL |
Re:
Theraspheres and FDA approval
|
|
vrs37
|
23 |
11K |
1 |
01/04/21 |
01/04/21 |
ASX - By Stock
|
23
|
11K
|
1
|
|
ASX - By Stock
|
OSL |
Re:
Theraspheres and FDA approval
|
|
vrs37
|
23 |
11K |
2 |
01/04/21 |
01/04/21 |
ASX - By Stock
|
23
|
11K
|
2
|
|
ASX - By Stock
|
OSL |
Re:
Theraspheres and FDA approval
|
|
vrs37
|
23 |
11K |
3 |
01/04/21 |
01/04/21 |
ASX - By Stock
|
23
|
11K
|
3
|
|
ASX - By Stock
|
OSL |
Re:
Ann: Half Yearly Report and Accounts
|
|
vrs37
|
60 |
30K |
1 |
26/03/21 |
26/03/21 |
ASX - By Stock
|
60
|
30K
|
1
|
|
ASX - By Stock
|
OSL |
Re:
Ann: Half Yearly Report and Accounts
|
|
vrs37
|
60 |
30K |
4 |
25/03/21 |
25/03/21 |
ASX - By Stock
|
60
|
30K
|
4
|
|
ASX - By Stock
|
NOX |
Re:
Ann: Noxopharm IONIC Immuno-Oncology Trial Commences
|
|
vrs37
|
14 |
6.3K |
5 |
19/03/21 |
19/03/21 |
ASX - By Stock
|
14
|
6.3K
|
5
|
|
ASX - By Stock
|
NOX |
Re:
Ann: Noxopharm IONIC Immuno-Oncology Trial Commences
|
|
vrs37
|
14 |
6.3K |
9 |
19/03/21 |
19/03/21 |
ASX - By Stock
|
14
|
6.3K
|
9
|
|
ASX - By Stock
|
BIT |
Re:
HIV SARS Covid. Biotron promises and delivers.
|
|
vrs37
|
8 |
6.1K |
9 |
14/03/21 |
14/03/21 |
ASX - By Stock
|
8
|
6.1K
|
9
|
|
ASX - By Stock
|
BIT |
Re:
Ann: Lead Series for SARS-COV-2 Program
|
|
vrs37
|
115 |
45K |
2 |
14/03/21 |
14/03/21 |
ASX - By Stock
|
115
|
45K
|
2
|
|
ASX - By Stock
|
BIT |
Re:
Ann: Lead Series for SARS-COV-2 Program
|
|
vrs37
|
115 |
45K |
1 |
14/03/21 |
14/03/21 |
ASX - By Stock
|
115
|
45K
|
1
|
|
ASX - By Stock
|
BIT |
Re:
Ann: Lead Series for SARS-COV-2 Program
|
|
vrs37
|
115 |
45K |
4 |
14/03/21 |
14/03/21 |
ASX - By Stock
|
115
|
45K
|
4
|
|
ASX - By Stock
|
NOX |
Re:
Ann: LuPIN Survival Outcome Confirmed by Conference Presentation
|
|
vrs37
|
25 |
7.5K |
3 |
15/02/21 |
15/02/21 |
ASX - By Stock
|
25
|
7.5K
|
3
|
|
ASX - By Stock
|
NOX |
Re:
Ann: LuPIN Survival Outcome Confirmed by Conference Presentation
|
|
vrs37
|
25 |
7.5K |
2 |
15/02/21 |
15/02/21 |
ASX - By Stock
|
25
|
7.5K
|
2
|
|
ASX - By Stock
|
NOX |
Re:
LuPIN abstract
|
|
vrs37
|
33 |
10K |
3 |
12/02/21 |
12/02/21 |
ASX - By Stock
|
33
|
10K
|
3
|
|
ASX - By Stock
|
BIT |
Re:
FURTHER PROOF BIOTRON IS THE MONEY SHOT! HOLY GRAIL!
|
|
vrs37
|
80 |
26K |
7 |
11/02/21 |
11/02/21 |
ASX - By Stock
|
80
|
26K
|
7
|
|
ASX - By Stock
|
NOX |
Re:
LuPIN abstract
|
|
vrs37
|
33 |
10K |
2 |
10/02/21 |
10/02/21 |
ASX - By Stock
|
33
|
10K
|
2
|
|
ASX - By Stock
|
NOX |
Re:
LuPIN abstract
|
|
vrs37
|
33 |
10K |
3 |
10/02/21 |
10/02/21 |
ASX - By Stock
|
33
|
10K
|
3
|
|
ASX - By Stock
|
NOX |
Re:
LuPIN abstract
|
|
vrs37
|
33 |
10K |
2 |
10/02/21 |
10/02/21 |
ASX - By Stock
|
33
|
10K
|
2
|
|
ASX - By Stock
|
NOX |
Re:
BMS woes continue
|
|
vrs37
|
11 |
3.3K |
2 |
08/01/21 |
08/01/21 |
ASX - By Stock
|
11
|
3.3K
|
2
|
|
ASX - By Stock
|
NOX |
Re:
BMS woes continue
|
|
vrs37
|
11 |
3.3K |
2 |
08/01/21 |
08/01/21 |
ASX - By Stock
|
11
|
3.3K
|
2
|
|
ASX - By Stock
|
NOX |
Re:
BMS woes continue
|
|
vrs37
|
11 |
3.3K |
2 |
08/01/21 |
08/01/21 |
ASX - By Stock
|
11
|
3.3K
|
2
|
|
ASX - By Stock
|
OSL |
Re:
Media
|
|
vrs37
|
18 |
13K |
0 |
08/01/21 |
08/01/21 |
ASX - By Stock
|
18
|
13K
|
0
|
|
ASX - By Stock
|
OSL |
Re:
Media
|
|
vrs37
|
18 |
13K |
0 |
08/01/21 |
08/01/21 |
ASX - By Stock
|
18
|
13K
|
0
|
|
ASX - By Stock
|
NOX |
Re:
BMS woes continue
|
|
vrs37
|
11 |
3.3K |
3 |
08/01/21 |
08/01/21 |
ASX - By Stock
|
11
|
3.3K
|
3
|
|
ASX - By Stock
|
NOX |
Re:
Ann: Pre-Clinical Breakthrough Discovery Set to Expand Pipeline
|
|
vrs37
|
11 |
5.2K |
5 |
10/12/20 |
10/12/20 |
ASX - By Stock
|
11
|
5.2K
|
5
|
|
ASX - By Stock
|
OSL |
Re:
Ann: Termination of Mr Daniel Kenny as Chief Executive Officer
|
|
vrs37
|
64 |
44K |
0 |
03/12/20 |
03/12/20 |
ASX - By Stock
|
64
|
44K
|
0
|
|
ASX - By Stock
|
OSL |
Re:
Ann: Termination of Mr Daniel Kenny as Chief Executive Officer
|
|
vrs37
|
64 |
44K |
2 |
02/12/20 |
02/12/20 |
ASX - By Stock
|
64
|
44K
|
2
|
|
ASX - By Stock
|
OSL |
Re:
Ann: OncoSil receives Swiss regulatory approval
|
|
vrs37
|
61 |
27K |
2 |
27/11/20 |
27/11/20 |
ASX - By Stock
|
61
|
27K
|
2
|
|
ASX - By Stock
|
OSL |
Re:
Ann: OncoSil receives Swiss regulatory approval
|
|
vrs37
|
61 |
27K |
1 |
27/11/20 |
27/11/20 |
ASX - By Stock
|
61
|
27K
|
1
|
|
ASX - By Stock
|
OSL |
Re:
Ann: OncoSil receives Swiss regulatory approval
|
|
vrs37
|
61 |
27K |
1 |
27/11/20 |
27/11/20 |
ASX - By Stock
|
61
|
27K
|
1
|
|
ASX - By Stock
|
NOX |
Re:
BMS NOX to partner on pilot study
|
|
vrs37
|
7 |
2.4K |
3 |
26/11/20 |
26/11/20 |
ASX - By Stock
|
7
|
2.4K
|
3
|
|
ASX - By Stock
|
NOX |
Re:
BMS NOX to partner on pilot study
|
|
vrs37
|
7 |
2.4K |
3 |
26/11/20 |
26/11/20 |
ASX - By Stock
|
7
|
2.4K
|
3
|
|
ASX - By Stock
|
NOX |
Re:
BMS NOX to partner on pilot study
|
|
vrs37
|
7 |
2.4K |
2 |
26/11/20 |
26/11/20 |
ASX - By Stock
|
7
|
2.4K
|
2
|
|
ASX - By Stock
|
OSL |
Re:
Ann: OncoSil receives Swiss regulatory approval
|
|
vrs37
|
61 |
27K |
2 |
14/11/20 |
14/11/20 |
ASX - By Stock
|
61
|
27K
|
2
|
|
ASX - By Stock
|
OSL |
Re:
Ann: OncoSil receives Swiss regulatory approval
|
|
vrs37
|
61 |
27K |
3 |
06/11/20 |
06/11/20 |
ASX - By Stock
|
61
|
27K
|
3
|
|
ASX - By Stock
|
OSL |
Re:
Bell Potter Report (inc SP valuation)
|
|
vrs37
|
15 |
10K |
2 |
30/10/20 |
30/10/20 |
ASX - By Stock
|
15
|
10K
|
2
|
|
ASX - By Stock
|
OSL |
Re:
Bell Potter Report (inc SP valuation)
|
|
vrs37
|
15 |
10K |
2 |
30/10/20 |
30/10/20 |
ASX - By Stock
|
15
|
10K
|
2
|
|
ASX - By Stock
|
OSL |
Re:
Public Funding of Oncosil in Australia
|
|
vrs37
|
8 |
3.7K |
0 |
29/10/20 |
29/10/20 |
ASX - By Stock
|
8
|
3.7K
|
0
|
|